Synovus Financial’s Galectin Therapeutics GALT Stock Holding History

Synovus Financial’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$203K	Hold	48,000	–	–	﹤0.01%	915
2025 Q2	$101K	Hold	48,000	–	–	﹤0.01%	899
2025 Q1	$58.6K	Hold	48,000	–	–	﹤0.01%	888
2024 Q4	$61.9K	Hold	48,000	–	–	﹤0.01%	862
2024 Q3	$132K	Hold	48,000	–	–	﹤0.01%	890
2024 Q2	$108K	Hold	48,000	–	–	﹤0.01%	829
2024 Q1	$115K	Hold	48,000	–	–	﹤0.01%	830
2023 Q4	$79.7K	Hold	48,000	–	–	﹤0.01%	811
2023 Q3	$92.2K	Hold	48,000	–	–	﹤0.01%	823
2023 Q2	$69.1K	Hold	48,000	–	–	﹤0.01%	827
2023 Q1	$101K	Hold	48,000	–	–	﹤0.01%	810
2022 Q4	$54.2K	Hold	48,000	–	–	﹤0.01%	845
2022 Q3	$78K	Hold	48,000	–	–	﹤0.01%	828
2022 Q2	$63K	Hold	48,000	–	–	﹤0.01%	829
2022 Q1	$77K	Hold	48,000	–	–	﹤0.01%	834
2021 Q4	$99K	Buy	+48,000	New	+$137K	﹤0.01%	845

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Synovus Financial's GALT Position: Q3 2025 in Review

Synovus Financial held its Galectin Therapeutics (GALT) position steady in Q3 2025 at 48,000 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #915.

Synovus Financial first reported a position in GALT in Q4 2021 and has held it in 16 quarters since. 84 funds tracked by Wall St. Rank hold GALT as of Q3 2025.

Synovus Financial held 48,000 shares of Galectin Therapeutics worth $203K as of Q3 2025.
Synovus Financial left its Galectin Therapeutics share count unchanged in Q3 2025.
Galectin Therapeutics made up ﹤0.01% of Synovus Financial's portfolio in Q3 2025, its #915 holding.
Synovus Financial first reported a position in Galectin Therapeutics in Q4 2021 and has held it in 16 quarters since.
84 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2025.

Based on Synovus Financial's 13F filing for Q3 2025, filed 7 Nov 2025.